United Therapeutics Corporation (UTHR) on Decifer

Decifer ranks UTHR number 110 of 270 tracked names on durable business quality.

Why it ranks here

• It earns strong returns on the money it puts to work, around 16% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is growing about 11% a year and profits grew 14% over the past year.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• And it returns cash to shareholders.
• Returns of 16% and 11% revenue growth show quality, but no funded role and momentum of 4 out of 35 limit near-term growth appeal.

The current read

The evidence on UTHR lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Next-Gen Genetic & RNA/Antibody Therapeutics: Platform breakthroughs in RNA interference, redosable gene therapy and antibody engineering are converting once-undruggable and orphan targets into commercial therapies.

Read the full UTHR research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.